Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of K-911 vs latanoprost in primary open-angle glaucoma or ocular hypertension
jRCT2051250050Phase 3Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of K-911 in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Change from baseline in intraocular pressure at week 2 (16:00), Change from baseline in intraocular pressure at week 4 (16:00) and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
K-911
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2051250050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250050.